Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Elevated soluble LOX-1 predicts risk of first-time myocardial infarction

Schiopu, Alexandru LU orcid ; Björkbacka, Harry LU orcid ; Narasimhan, Gayathri LU ; Loong, Bi Juin LU ; Engström, Gunnar LU ; Melander, Olle LU orcid ; Orho-Melander, Marju LU and Nilsson, Jan LU (2023) In Annals of Medicine 55(2).
Abstract

Background: There is an unmet clinical need for novel therapies addressing the residual risk in patients receiving guideline preventive therapy for coronary heart disease. Experimental studies have identified a pro-atherogenic role of the oxidized LDL receptor LOX-1. We investigated the association between circulating soluble LOX-1 (sLOX-1) and the risk for development of myocardial infarction. Methods: The study subjects (n = 4658) were part of the Malmö Diet and Cancer study. The baseline investigation was carried out 1991-1994 and the incidence of cardiovascular events monitored through national registers during a of 19.5 ± 4.9 years follow-up. sLOX-1 and other biomarkers were analyzed by proximity extension assay and ELISA in... (More)

Background: There is an unmet clinical need for novel therapies addressing the residual risk in patients receiving guideline preventive therapy for coronary heart disease. Experimental studies have identified a pro-atherogenic role of the oxidized LDL receptor LOX-1. We investigated the association between circulating soluble LOX-1 (sLOX-1) and the risk for development of myocardial infarction. Methods: The study subjects (n = 4658) were part of the Malmö Diet and Cancer study. The baseline investigation was carried out 1991-1994 and the incidence of cardiovascular events monitored through national registers during a of 19.5 ± 4.9 years follow-up. sLOX-1 and other biomarkers were analyzed by proximity extension assay and ELISA in baseline plasma. Results: Subjects in the highest tertile of sLOX-1 had an increased risk of myocardial infarction (hazard ratio (95% CI) 1.76 (1.40-2.21) as compared with those in the lowest tertile. The presence of cardiovascular risk factors was related to elevated sLOX-1, but the association between sLOX-1 and risk of myocardial infarction remained significant when adjusting for risk factors. Conclusions: In this prospective population study we found an association between elevated sLOX-1, the presence of carotid disease and the risk for first-time myocardial infarction. Taken together with previous experimental findings of a pro-atherogenic role of LOX-1, this observation supports LOX-1 inhibition as a possible target for prevention of myocardial infarction.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
disease mechanisms, LOX-1, myocardial infarction, population cohort, risk prediction
in
Annals of Medicine
volume
55
issue
2
article number
2296552
publisher
Taylor & Francis
external identifiers
  • pmid:38134912
  • scopus:85180713323
ISSN
0785-3890
DOI
10.1080/07853890.2023.2296552
language
English
LU publication?
yes
additional info
Publisher Copyright: © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
id
86a60f72-22c3-493e-a80f-8f8cc7202614
date added to LUP
2024-02-05 10:02:33
date last changed
2025-10-21 19:35:12
@article{86a60f72-22c3-493e-a80f-8f8cc7202614,
  abstract     = {{<p>Background: There is an unmet clinical need for novel therapies addressing the residual risk in patients receiving guideline preventive therapy for coronary heart disease. Experimental studies have identified a pro-atherogenic role of the oxidized LDL receptor LOX-1. We investigated the association between circulating soluble LOX-1 (sLOX-1) and the risk for development of myocardial infarction. Methods: The study subjects (n = 4658) were part of the Malmö Diet and Cancer study. The baseline investigation was carried out 1991-1994 and the incidence of cardiovascular events monitored through national registers during a of 19.5 ± 4.9 years follow-up. sLOX-1 and other biomarkers were analyzed by proximity extension assay and ELISA in baseline plasma. Results: Subjects in the highest tertile of sLOX-1 had an increased risk of myocardial infarction (hazard ratio (95% CI) 1.76 (1.40-2.21) as compared with those in the lowest tertile. The presence of cardiovascular risk factors was related to elevated sLOX-1, but the association between sLOX-1 and risk of myocardial infarction remained significant when adjusting for risk factors. Conclusions: In this prospective population study we found an association between elevated sLOX-1, the presence of carotid disease and the risk for first-time myocardial infarction. Taken together with previous experimental findings of a pro-atherogenic role of LOX-1, this observation supports LOX-1 inhibition as a possible target for prevention of myocardial infarction.</p>}},
  author       = {{Schiopu, Alexandru and Björkbacka, Harry and Narasimhan, Gayathri and Loong, Bi Juin and Engström, Gunnar and Melander, Olle and Orho-Melander, Marju and Nilsson, Jan}},
  issn         = {{0785-3890}},
  keywords     = {{disease mechanisms; LOX-1; myocardial infarction; population cohort; risk prediction}},
  language     = {{eng}},
  number       = {{2}},
  publisher    = {{Taylor & Francis}},
  series       = {{Annals of Medicine}},
  title        = {{Elevated soluble LOX-1 predicts risk of first-time myocardial infarction}},
  url          = {{http://dx.doi.org/10.1080/07853890.2023.2296552}},
  doi          = {{10.1080/07853890.2023.2296552}},
  volume       = {{55}},
  year         = {{2023}},
}